Cambridge Healthtech ’s 4th Annual
Enabling Technologies for Circulating Biomarkers
Advancing Technologies for Clinical Utilities
August 20-21, 2019
The technologies in the liquid biopsy field have been maturing rapidly and are on their path to revolutionize the management of cancer patients. However, in the increasingly crowded landscape of all the diagnostic approaches, it can be overwhelming to
identify the key technologies that are showing promises and have
Day 1 | Day 2
Recommended Short Course*
SC3: Emerging Applications of ctDNA
This short course will cover cutting edge applications and clinical trials that use ctDNA for monitoring, minimal residual disease, and plasma tumor mutation burden. The background basics, the technologies, the clinical evidence out there so far, and the highlights of the prospective designs that are underway will be discussed.
SC9: Liquid Biopsies based on Extracellular Vesicles: Prospects, Challenges, and Opportunities
Joshua T. Smith,
Extracellular vesicles (EVs) exhibit a number of properties that make them attractive as a rich source of biomarkers for disease diagnosis, treatment monitoring, and therapeutics, including their abundance in a wide breadth of bodily fluids, nucleic acid
*Separate registration required.
TUESDAY, AUGUST 20
7:30 am Registration and Morning Coffee
THE ERA OF MARKER COMBINATIONS
8:30 Chairperson’s Opening Remarks
G. Mike Makrigiorgos, PhD, Professor of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School
8:40 KEYNOTE PRESENTATION: Precision Medicine Using Liquid Biopsies: A New Paradigm for Managing Cancer Diseases
Steven A. Soper, PhD, Chemistry, Mechanical Engineering, BioEngineering, KUMC Cancer Center University of Kansas, Lawrence; Director, NIH Biotechnology Resource Center of BioModular Multi-Scale Systems for Precision Medicine
We are generating innovative microfluidic tools for selecting circulating markers from whole blood and determining the presence/absence of disease-specific molecular signatures secured from the liquid biopsy markers to guide therapy for a patient. The
microfluidics can process whole blood (≥1 mL) and search for CTCs, cfDNA, or exosomes and make them available for downstream molecular processing. I will talk extensively about our exosome isolation chip, and its use in several clinical examples
and securing molecular information from the affinity-selected exosomes. The exosome chip consists of 1.4 million pillars that contain surface-immobilized antibodies directed against antigens from cancer cells that are
9:10 Opportunities and Challenges for Liquid Biopsies in the Fight Against Cancer
This presentation will address the need for better focus on the clinical decision making support being enabled by liquid biopsy-based assays in the context of new enabling technologies that are shaping the landscape of possibilities. The persistent need
for standards development in this field to qualify new assays are
9:40 Multi-Parametric Liquid Biopsy Analysis in Metastatic Prostate Cancer
Amir Goldkorn, MD, Associate Professor of Medicine, Co-Leader, Translational & Clinical Science Program; Director, Circulating Tumor Cell Research Core, USC Norris Comprehensive Cancer Center & Keck School of Medicine; Chair, Prostate Cancer Organ Site Translational Medicine, SWOG
Multiparametric liquid biopsy profiles were successfully generated for each patient and time point, demonstrating the feasibility of this approach and highlighting shared as well as unique cancer-relevant alterations. With further refinement and validation in large cohorts, multiparametric liquid biopsies can optimally integrate disparate but clinically informative data sets and maximize their utility for molecularly directed, real-time patient management.
10:10 Coffee Break in the Exhibit Hall with Poster Viewing
10:55 Chairperson’s Remarks
G. Mike Makrigiorgos,
11:00 Multi-Omic Liquid Biopsy Platform
Sam Hanash, MD,
Multiple technologies are currently being explored for liquid biopsy applications beyond genomics, including proteomics, metabolomics,
11:30 Analysis of Therapeutically-Relevant Markers in Circulating Tumor Cells
Shana O. Kelley,
Arturo Ramirez, Director, Oncology R&D, RareCyte, Inc.
This talk will highlight the unique benefits of the RareCyte platform for CTC characterization. It will present the method to transfer nucleated cells from whole blood to slides as well as immunofluorescence staining to identify CTCs and phenotypically characterize clinically relevant biomarkers. Clinical studies were performed comparing our platform to CellSearch® and single CTCs were isolated for next generation sequencing to obtain molecular information about the tumor via liquid biopsy.
12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:00 Cookie & Refreshment Break in the Exhibit Hall with Poster Viewing
DETECTION AND ANALYSIS OF CTCs AND OTHER TUMOR-ASSOCIATED CELLS
1:30 Chairperson’s Remarks
Steven A. Soper,
1:35 Targeting CTC Cytoskeletal Alterations to Reduce Metastasis
2:05 Isolation of Circulating Tumor Cells in Non-Small-Cell-Lung-Cancer Patients Using a Multi-Flow Microfluidic Channel
Our device is constructed and configured based on the phenomenal effect of size-dependent inertial migration. The recovery rate of >93%
2:35 Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies from Patients with Liver Disease
In this work, we used the iChip platform to detect CECs in patients with CLD but without HCC and to phenotypically discriminate between CECs in patients with and without HCC.
3:05 Sponsored Presentation (Opportunity Available)
3:35 Refreshment Break in the Exhibit Hall with Poster Viewing
ADVANCES IN CIRCULATING NUCLEIC-ACID TECHNOLOGIES
4:25 Chairperson’s Remarks
G. Mike Makrigiorgos,
4:30 Novel Digital PCR and Mutation Enrichment Technologies for the Analysis of Clinically Relevant DNA Alterations in Liquid Biopsies
G. Mike Makrigiorgos,
With the increasing interest in treatment assessment using liquid biopsy and circulating DNA, sensitive and multiplexed detection of tumor-derived alterations in blood are desirable. We provide novel forms of digital PCR, as well as mutation enrichment-based
5:00 Phospho-sRNA-seq Enables Plasma mRNA/lncRNA Transcriptome Profiling as a Liquid Biopsy Approach
Ryan M. Spengler,
We present a modified RNA-seq methodology, called
5:30 Sponsored Presentation (Opportunity Available)
6:00 Wine & Cheese Pairing Welcome Reception in the Exhibit Hall with Poster Viewing
7:00 Close of Day
Day 1 | Day 2
WEDNESDAY, AUGUST 21
7:15 am Registration
7:30 Problem Solving Breakout Discussions with Continental Breakfast
Analytical Considerations for Liquid Biopsy RNA-seq
Moderator: Ryan M. Spengler, PhD, Postdoctoral Fellow, Muneesh Tewari Laboratory, Hematology/Oncology, University of Michigan
Challenges for Early Cancer Detection
Moderator: Michael J. Heller, PhD, Distinguished Scientist, Knight Cancer Institute at Oregon Health & Science University (OHSU), Center for Cancer Early Detection and Research (CEDAR); Professor Emeritus, Bioengineering and Nanoengineering, University of California San Diego
EXOSOME PROFILING AND ANALYSIS
8:25 Chairperson’s Remarks
8:30 Ultrasensitive Detection of Circulating Exosomes with a 3D-Nanopatterned Microfluidic Chip
Here, we show that a microfluidic chip designed with self-assembled three-dimensional herringbone nanopatterns can detect low levels of
9:00 AC Electrokinetic Chip Device for Rapid Isolation and Integrated Analysis of Exosome and cf-DNA Biomarkers from Cancer Patient Blood Samples
New multi-omic approaches for different biomarkers is becoming a viable strategy for liquid biopsy diagnostics and early cancer detection.
9:20 Nanoplasmonic Exosome (
Exosomes have emerged as promising circulating biomarkers for diagnosis and prognosis of various cancer types. This presentation will discuss
9:40 High Precision Isolation and Analysis of Exosomes
Daniel T. Chiu,
We have recently developed microfluidic and nanofluidic systems for the isolation and analysis of exosomes, offering detailed molecular information with single-exosome resolution. Here, we will describe our technical approach, device performance, and the new information we learned about exosomes as revealed by the new measurements.
10:00 Sponsored Presentation (Opportunity Available)
10:30 Coffee Break in the Exhibit Hall with Poster Viewing
11:30 Plenary Keynote Session
11:30 Chairperson’s Remarks
Charles Mathews, Principal, ClearView Healthcare Partners
11:40 Plenary Keynote Presentation: FDA Updates: Now and Looking to the Future
Tim Stenzel, MD,
Introduction and background of the new Office Director of OIR and updates on precision medicine and other initiatives at the FDA.
12:10-1:05 pm Plenary Keynote Discussion: Proposals and Solutions for Diagnostic Reform Including Oversight of Laboratory Developed Tests (LDTs)
Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition
- How are stakeholders influencing congressional activity on the Verifying Accurate Leading-edge IVCT Development (VALID) Act?
- How will the VALID Act change the current oversight landscape for diagnostics, including LDTs?
- How are policymakers addressing the role of CMS and CLIA in the VALID Act?
- How will increased regulatory and oversight activities at the FDA affect the diagnostics industry?
- What impact will changes in diagnostics regulation and oversight have on patient care?
Julie Khani, MPA, President, American Clinical Laboratory Association (ACLA)
Donald E. Horton, Jr., Senior Vice President, Global Government Relations & Public Policy, Laboratory Corporation of America Holdings
Susan Van Meter, Executive Director, AdvaMedDx
Tara Burke, PhD, Senior Director, Public Policy & Advocacy, Association for Molecular Pathology (AMP)
Laura Lasiter, PhD, Science Policy Analyst, Friends of Cancer Research
1:05 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:35 End of Enabling Technologies for Circulating Biomarkers
* The program is subject to change without notice, due to unforeseen reason.